Cargando…

The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial

As a mediator between lipid metabolism dysfunction, oxidative stress and inflammation, oxidized low-density lipoprotein (oxLDL) is a promising therapeutical target in a wide range of metabolic diseases. In mice, pneumococcal immunization increases anti-phosphorylcholine and oxLDL antibody levels, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiri-Sverdlov, Ronit, dos Reis, Inês Magro, Oligschlaeger, Yvonne, Hendrikx, Tim, Meesters, Dennis M., Vanclooster, Annick, Vanhoutvin, Nele, Koek, Ger H., Westerterp, Marit, Binder, Christoph J., Cassiman, David, Houben, Tom
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831333/
https://www.ncbi.nlm.nih.gov/pubmed/33477615
http://dx.doi.org/10.3390/antiox10010129
_version_ 1783641612836929536
author Shiri-Sverdlov, Ronit
dos Reis, Inês Magro
Oligschlaeger, Yvonne
Hendrikx, Tim
Meesters, Dennis M.
Vanclooster, Annick
Vanhoutvin, Nele
Koek, Ger H.
Westerterp, Marit
Binder, Christoph J.
Cassiman, David
Houben, Tom
author_facet Shiri-Sverdlov, Ronit
dos Reis, Inês Magro
Oligschlaeger, Yvonne
Hendrikx, Tim
Meesters, Dennis M.
Vanclooster, Annick
Vanhoutvin, Nele
Koek, Ger H.
Westerterp, Marit
Binder, Christoph J.
Cassiman, David
Houben, Tom
author_sort Shiri-Sverdlov, Ronit
collection PubMed
description As a mediator between lipid metabolism dysfunction, oxidative stress and inflammation, oxidized low-density lipoprotein (oxLDL) is a promising therapeutical target in a wide range of metabolic diseases. In mice, pneumococcal immunization increases anti-phosphorylcholine and oxLDL antibody levels, and reduces atherosclerosis, non-alcoholic steatohepatitis and Niemann–Pick disease burden. These findings suggest that pneumococcal vaccination may be a useful preventive and therapeutical strategy in metabolic disease patients. In this pilot clinical trial, our aim was to determine whether the administration of a pneumococcal vaccine increases anti-phosphorylcholine and anti-oxLDL antibody levels in metabolic disease patients. The following patients were enrolled: four patients with familial partial lipodystrophy (all women, mean age 32 years old); three familial hypercholesterolemia patients (one girl, two boys; mean age 13 years); and two Niemann–Pick type B (NP-B) patients (two men, mean age 37.5 years old). Participants received one active dose of a 13-valent conjugated pneumococcal vaccine (Prevenar 13) and were followed-up for four weeks. Four weeks after Prevenar 13 vaccination, no differences were observed in patients’ levels of anti-oxLDL IgM or IgG antibodies. In addition, we observed a reduction in anti-phosphorylcholine (anti-PC) IgM antibody levels, whereas no differences were observed in anti-PC IgG antibody titers. These findings indicate that Prevenar 13 vaccination does not induce an immune response against oxLDL in patients with metabolic diseases. Therefore, Prevenar 13 is not suited to target the metabolic disruptor and pro-inflammatory mediator oxLDL in patients.
format Online
Article
Text
id pubmed-7831333
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78313332021-01-26 The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial Shiri-Sverdlov, Ronit dos Reis, Inês Magro Oligschlaeger, Yvonne Hendrikx, Tim Meesters, Dennis M. Vanclooster, Annick Vanhoutvin, Nele Koek, Ger H. Westerterp, Marit Binder, Christoph J. Cassiman, David Houben, Tom Antioxidants (Basel) Article As a mediator between lipid metabolism dysfunction, oxidative stress and inflammation, oxidized low-density lipoprotein (oxLDL) is a promising therapeutical target in a wide range of metabolic diseases. In mice, pneumococcal immunization increases anti-phosphorylcholine and oxLDL antibody levels, and reduces atherosclerosis, non-alcoholic steatohepatitis and Niemann–Pick disease burden. These findings suggest that pneumococcal vaccination may be a useful preventive and therapeutical strategy in metabolic disease patients. In this pilot clinical trial, our aim was to determine whether the administration of a pneumococcal vaccine increases anti-phosphorylcholine and anti-oxLDL antibody levels in metabolic disease patients. The following patients were enrolled: four patients with familial partial lipodystrophy (all women, mean age 32 years old); three familial hypercholesterolemia patients (one girl, two boys; mean age 13 years); and two Niemann–Pick type B (NP-B) patients (two men, mean age 37.5 years old). Participants received one active dose of a 13-valent conjugated pneumococcal vaccine (Prevenar 13) and were followed-up for four weeks. Four weeks after Prevenar 13 vaccination, no differences were observed in patients’ levels of anti-oxLDL IgM or IgG antibodies. In addition, we observed a reduction in anti-phosphorylcholine (anti-PC) IgM antibody levels, whereas no differences were observed in anti-PC IgG antibody titers. These findings indicate that Prevenar 13 vaccination does not induce an immune response against oxLDL in patients with metabolic diseases. Therefore, Prevenar 13 is not suited to target the metabolic disruptor and pro-inflammatory mediator oxLDL in patients. MDPI 2021-01-18 /pmc/articles/PMC7831333/ /pubmed/33477615 http://dx.doi.org/10.3390/antiox10010129 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shiri-Sverdlov, Ronit
dos Reis, Inês Magro
Oligschlaeger, Yvonne
Hendrikx, Tim
Meesters, Dennis M.
Vanclooster, Annick
Vanhoutvin, Nele
Koek, Ger H.
Westerterp, Marit
Binder, Christoph J.
Cassiman, David
Houben, Tom
The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial
title The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial
title_full The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial
title_fullStr The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial
title_full_unstemmed The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial
title_short The Influence of a Conjugated Pneumococcal Vaccination on Plasma Antibody Levels against Oxidized Low-Density Lipoprotein in Metabolic Disease Patients: A Single-Arm Pilot Clinical Trial
title_sort influence of a conjugated pneumococcal vaccination on plasma antibody levels against oxidized low-density lipoprotein in metabolic disease patients: a single-arm pilot clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831333/
https://www.ncbi.nlm.nih.gov/pubmed/33477615
http://dx.doi.org/10.3390/antiox10010129
work_keys_str_mv AT shirisverdlovronit theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT dosreisinesmagro theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT oligschlaegeryvonne theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT hendrikxtim theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT meestersdennism theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT vancloosterannick theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT vanhoutvinnele theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT koekgerh theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT westerterpmarit theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT binderchristophj theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT cassimandavid theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT houbentom theinfluenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT shirisverdlovronit influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT dosreisinesmagro influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT oligschlaegeryvonne influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT hendrikxtim influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT meestersdennism influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT vancloosterannick influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT vanhoutvinnele influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT koekgerh influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT westerterpmarit influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT binderchristophj influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT cassimandavid influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial
AT houbentom influenceofaconjugatedpneumococcalvaccinationonplasmaantibodylevelsagainstoxidizedlowdensitylipoproteininmetabolicdiseasepatientsasinglearmpilotclinicaltrial